Ligand Pharmaceuticals Incorporated or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Giants' Revenue Race: Ligand vs. Travere

__timestampLigand Pharmaceuticals IncorporatedTravere Therapeutics, Inc.
Wednesday, January 1, 20146453800028203205
Thursday, January 1, 20157191400099892000
Friday, January 1, 2016108973000133591000
Sunday, January 1, 2017141102000154937000
Monday, January 1, 2018251453000164246000
Tuesday, January 1, 2019120282000175338000
Wednesday, January 1, 2020186419000198321000
Friday, January 1, 2021277133000227490000
Saturday, January 1, 2022196245000212018000
Sunday, January 1, 2023131314000145238000
Loading chart...

Data in motion

A Decade of Revenue Rivalry: Ligand vs. Travere

In the competitive landscape of biotechnology, Ligand Pharmaceuticals and Travere Therapeutics have been vying for revenue supremacy over the past decade. From 2014 to 2023, Ligand's revenue surged by approximately 103%, peaking in 2021 with a remarkable 278 million USD. Meanwhile, Travere's revenue grew by an impressive 411%, reaching its zenith in 2021 with 227 million USD.

Ligand's revenue trajectory shows a significant leap in 2018, with a 78% increase from the previous year, while Travere's steady growth is marked by a consistent upward trend, particularly between 2015 and 2020. Despite Ligand's higher peak, Travere's consistent growth rate suggests a robust business model. As both companies continue to innovate, the question remains: who will lead the revenue race in the coming years?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025